Advertisement

Transcranial Low Voltage Pulsed Electromagnetic Fields in Patients with Treatment-Resistant Depression

      Background

      Approximately 30% of patients with depression are resistant to antidepressant drugs. Repetitive transcranial magnetic stimulation (rTMS) has been found effective in combination with antidepressants in this patient group. The aim of this study was to evaluate the antidepressant effect of a new principle using low-intensity transcranially applied pulsed electromagnetic fields (T-PEMF) in combination with antidepressants in patients with treatment-resistant depression.

      Methods

      This was a sham-controlled double-blind study comparing 5 weeks of active or sham T-PEMF in patients with treatment-resistant major depression. The antidepressant treatment, to which patients had been resistant, was unchanged 4 weeks before and during the study period. Weekly assessments were performed using both clinician-rated and patient-rated scales. The T-PEMF equipment was designed as a helmet containing seven separate coils located over the skull that generated an electrical field in tissue with orders of magnitude weaker than those generated by rTMS equipment.

      Results

      Patients on active T-PEMF showed a clinically and statistically significant better outcome than patients treated with sham T-PEMF, with an onset of action within the first weeks of therapy. Effect size on the Hamilton 17-item Depression Rating Scale was .62 (95% confidence interval .21–1.02). Treatment-emergent side effects were few and mild.

      Conclusion

      The T-PEMF treatment was superior to sham treatment in patients with treatment-resistant depression. Few side effects were observed. Mechanism of the antidepressant action, in light of the known effects of PEMF stimulation to the brain, is discussed.

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Biological Psychiatry
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Stimpson N.
        • Agrawal N.
        • Lewis G.
        Randomised controlled trials investigating pharmacological and psychological interventions for treatment-refractory depression.
        Br J Psychiatry. 2002; 181: 284-294
        • Thamsborg G.
        • Floresco A.
        • Oturai P.
        • Fallentin E.
        • Tritsaris F.
        • Dissing S.
        Treatment of knee osteoarthritis with pulsed electromagnetic fields: A randomized, double-blind, placebo-controlled study.
        Osteoarthritis Cartilage. 2005; 13: 575-581
        • Trock D.H.
        • Bollet A.J.
        • Markoll R.
        The effect of pulsed electromagnetic fields in the treatment of osteoarthritis of the knee and cervical spine.
        J Rheumatol. 1994; 21: 1903-1911
        • Tepper O.M.
        • Callaghan M.J.
        • Chang E.I.
        • Galiano R.D.
        • Bhatt K.A.
        • Baharestani S.
        • et al.
        Electromagnetic fields increase in vitro and in vivo angiogenesis through endothelial release of FGF-2.
        FASEB J. 2004; 18: 1231-1233
        • Smith T.L.
        • Wong-Gibbons D.
        • Maultsby J.
        Microcirculatory effects of pulsed electromagnetic fields.
        J Orthop Res. 2004; 22: 80-84
        • Macias M.Y.
        • Battocletti J.H.
        • Sutton C.H.
        • Pintar F.A.
        • Maiman D.J.
        Directed and enhanced neurite growth with pulsed magnetic field stimulation.
        Bioelectromagnetics. 2000; 21: 272-286
        • Rahbek U.L.
        • Tritsaris K.
        • Dissing S.
        Interactions of low frequency, pulsed electromagnetic fields with living tissue: Biochemical responses and clinical results.
        Oral Biosci Med. 2005; 2: 29-40
        • Martiny K.
        Pulsed electromagnetic fields (PEMF) in treatment resistant depression.
        J Affect Disord. 2004; 78 (Poster presented at the International Society of Affective Disorders, Second Biennal International Conference, March 4–10, Cancun, Mexico): 124
        • Bech P.
        • Rasmussen N.-A.
        • Olsen L.R.
        • Noerholm V.
        • Abildgaard W.
        The sensitivity and specificity of the major depression inventory, using the Present State Examination as the index of diagnostic validity.
        J Affect Disord. 2001; 66: 159-164
        • Bretlau L.G.
        • Lunde M.
        • Lindberg L.
        • Undén M.
        • Dissing S.
        • Bech P.
        Repetitive transcranial magnetic stimulation (rTMS) in combination with escitalopram in patients with treatment-resistant major depression: A double-blind, randomised, sham-controlled trial.
        Pharmacopsychiatry. 2008; 41: 41-47
        • European Agency for the Evaluation of Medicinal Products
        Note for guidance on Good Clinical Practice.
        (CPMP/ICH/135/95) European Agency for the Evaluation of Medicinal Products, London1997
        • Sackheim H.A.
        The definition and meaning of treatment-resistant depression.
        J Clin Psychiatry. 2001; 62: 10-17
        • Sheehan D.V.
        • Lecrubier Y.
        • Sheehan K.H.
        • Amorim P.
        • Janavs J.
        • Weiller E.
        • et al.
        The Mini International Neuropsychiatric Interview (M.I.N.I.): The development and validation of a structured diagnostic psychiatric interview.
        J Clin Psychiatry. 1998; 59: 22-33
        • American Psychiatric Association
        Diagnostic and Statistical Manual of Mental Disorders.
        4th ed. DC American Psychiatric Association, Washington1994
        • Bech P.
        • Kastrup M.
        • Rafaelsen O.J.
        Mini-compendium of rating scales for states of anxiety depression mania schizophrenia with corresponding DSM-III syndromes.
        Acta Psychiatr Scand. 1986; 326: 1-37
        • Bech P.
        • Allerup P.
        • Gram L.F.
        • Reisby N.
        • Rosenberg R.
        • Jacobsen O.
        • et al.
        The Hamilton Depression Scale.
        Acta Psychiatr Scand. 1981; 63: 290-299
        • O'Sullivan R.L.
        • Fava M.
        • Agustin C.
        • Baer L.
        • Rosenbaum J.F.
        Sensitivity of the six-item Hamilton Depression Rating Scale.
        Acta Psychiatr Scand. 1997; 95: 379-384
        • Bech P.
        The Bech-Rafaelsen Melancholia Scale (MES) in clinical trials of therapies in depressive disorders: A 20-year review of its use as outcome measure.
        Acta Psychiatr Scand. 2002; 106: 252-264
        • Licht R.W.
        • Qvitzau S.
        • Allerup P.
        • Bech P.
        Validation of the Bech-Rafaelsen Melancholia Scale and the Hamilton Depression Scale in patients with major depression; is the total score a valid measure of illness severity?.
        Acta Psychiatr Scand. 2005; 111: 144-149
        • Bech P.
        Measuring the dimensions of psychological general well-being by the WHO-5.
        QoL Newsletter. 2004; 32: 15-16
        • Bech P.
        Rating scales for psychopathology, health status and quality of life.
        Springer, Berlin1993
        • Lingjaerde O.
        • Ahlfors U.G.
        • Bech P.
        • Dencker S.J.
        • Elgen K.
        The UKU side effect rating scale.
        Acta Psychiatr Scand Suppl. 1987; 334: 1-100
        • Brown H.
        • Prescott R.
        Applied Mixed Models in Medicine.
        Wiley, Chichester, UK1999
        • Stassen H.H.
        • Delini-Stula A.
        • Angst J.
        Time course of improvement under antidepressant treatment.
        Eur Neuropsychopharmacol. 1993; 3: 127-135
        • Uckun F.M.
        • Kurosaki T.
        • Jin J.
        • Jun X.
        • Morgan A.
        • Takata M.
        • et al.
        Exposure of B-lineage lymphoid cells to low energy electromagnetic fields stimulates Lyn kinase.
        J Biol Chem. 1995; 270: 27666-27670
        • Kozisek M.E.
        • Middlemas D.
        • Bylund D.B.
        Brain-derived neurotrophic factor and its receptor tropomyosin-related kinase B in the mechanism of action of antidepressant therapies.
        Pharmacol Ther. 2008; 117: 30-51
        • Evans S.J.
        • Choudary P.V.
        • Neal C.R.
        • Li J.Z.
        • Vawter M.P.
        • Tomita H.
        • et al.
        Dysregulation of the fibroblast growth factor system in major depression.
        Proc Natl Acad Sci U S A. 2004; 101: 15506-155011
        • Capone F.
        • Dileone M.
        • Profice P.
        • Pilato F.
        • Musumeci G.
        • Minicuci G.
        • et al.
        Does exposure to extremely low frequency magnetic fields produce functional changes in human brain?.
        J Neural Transm. 2009; 116: 257-265
        • López-Ibor J.J.
        • López-Ibor M.I.
        • Pastrana J.I.
        Transcranial magnetic stimulation.
        Curr Opin Psychiatry. 2008; 21: 640-644
        • Nitsche M.A.
        • Boggio P.S.
        • Fregni F.
        • Pascual-Leone A.
        Treatment of depression with transcranial direct current stimulation (tDCS): A review.
        Exp Neurol. 2009; 219: 14-19
        • Montgomery J.C.
        • Bodznick D.
        Signals and noise in the elasmobranch electrosensory system.
        J Exp Biol. 1999; 202: 1349-1355
        • Carrubba S.
        • Marino A.A.
        The effects of low-frequency environmental-strength electromagnetic fields on brain electrical activity: A critical review of the literature.
        Electromagn Biol Med. 2008; 27: 83-101